查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1864729

按產品類型、給藥途徑、分銷管道、最終用戶、處方狀態和劑型分類的減充血劑市場－2025-2032年全球預測

Decongestant Market by Product Type, Route Of Administration, Distribution Channel, End User, Prescription Status, Form - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，減充血劑市場規模將達到 115.9 億美元，複合年成長率為 6.45%。

關鍵市場統計數據
基準年 2024 70.3億美元
預計年份：2025年 74.8億美元
預測年份 2032 115.9億美元
複合年成長率 (%) 6.45%

對不斷發展的減充血劑生態系統進行簡要概述，重點關注需要經營團隊關注的臨床、監管和商業趨勢。

由於消費行為的改變、監管機構對安全性的日益重視以及醫療服務管道的不斷演進，減充血劑市場格局正經歷著快速變革。本執行摘要概述了影響產品開發和商業化的關鍵主題促進因素，並為後續章節提供了框架，這些章節將分析結構性變化、關稅影響、市場細分資訊、區域趨勢和競爭活動。本文檔旨在為高階決策者提供指導，幫助他們了解近期影響產品生命週期、供應鏈和分銷策略的關鍵因素。

產品創新、監管加強數位化分銷管道將如何重塑通鼻劑領域的競爭和商業策略

隨著技術創新、患者期望和醫療保健系統優先事項的交匯，鼻塞緩解劑市場正經歷變革性的變化。首先，劑型創新正在改變競爭動態。定量滴鼻劑噴劑和單劑量滴劑技術的進步實現了差異化的安全性，並提高了給藥的精確度。同時，與數位醫療的日益整合正在加速電子處方箋和線上藥局管道的普及，這也對產品包裝、病患教育和上市後監測要求產生了影響。

2025年關稅變化對緩解擁塞製造業供應鏈韌性、籌資策略和商業定價結構的下游影響

美國宣布的2025年關稅調整將產生一系列累積效應，影響原料採購、成品定價和供應商選擇。關稅調整將對依賴跨境採購活性藥物成分和包裝組件的製造商的成本結構產生顯著影響。因此，採購部門被迫重新評估其供應商組合，加快對替代供應商的資格認證，並重新談判供應合約以確保毛利率。

一個層級細分框架，解釋了產品形式、給藥途徑、通路和最終用戶人口統計特徵如何決定策略優先順序。

為了深入了解市場動態，我們著重研究了多種細分框架，這些框架定義了產品性能和客戶參與度。根據產品類型，市場分為眼藥水、滴鼻劑和片劑/膠囊。眼藥水類別進一步細分為多劑量和單劑量，滴鼻劑類別細分為定量和標準劑量，藥片/膠囊類別細分為緩釋性和速釋。這些分類指導著配方選擇、包裝設計和說明書設計。根據給藥途徑，我們研究了鼻腔和口服給藥市場，以揭示影響臨床診療建議的因素，包括臨床考慮、起效預期和患者偏好。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 消費者對不含糖、不含酒精且添加天然萃取物的鼻塞緩解糖漿的偏好日益成長，這增強了潔淨標示產品的吸引力。
  • 將新型乳化技術應用於局部減充血劑製劑中，以提高其黏膜吸收率
  • 擴大季節性減充血劑的直接面對消費者的訂閱模式，並提供個人化用藥提醒
  • 拓展植物來源精油吸入器（為尋求全面呼吸道緩解的人群）的電子商務管道
  • 對假麻黃堿銷售的監管審查力度加大，推動了無刺激性減充血劑替代品的創新。
  • 人們對具有雙重功效的減充血劑/抗組織胺藥物組合產品的興趣日益濃厚，這些產品可用於全年緩解過敏和鼻竇炎症狀。
  • 智慧型手機連接的鼻噴霧裝置的出現，使得追蹤使用情況和利用人工智慧最佳化劑量成為可能。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依產品類型分類的減充血劑市場

  • 眼藥水
    • 多劑量
    • 單一劑量
  • 滴鼻劑
    • 計量噴霧型
    • 標準噴霧
  • 片劑和膠囊
    • 緩釋性
    • 立即生效

9. 依給藥途徑分類的減充血劑市場

  • 鼻內給藥
  • 口服

第10章 按分銷管道分類的減充血劑市場

  • 醫院藥房
    • 私人的
    • 民眾
  • 網路藥房
    • 品牌官方網站
    • 第三方平台
  • 零售藥房
    • 連鎖藥局
    • 獨立藥房

第11章 以最終用戶分類的減充血劑市場

  • 成人
  • 老年人
  • 兒童
    • 青春期
    • 孩子
    • 嬰兒

第12章 依處方狀態分類的減充血劑市場

  • 非處方藥
  • 處方箋

第13章 按劑型分類的減充血劑市場

  • 液體
    • 暫停
    • 糖漿
  • 半固態
    • 凝膠
    • 軟膏
  • 固態劑型
    • 膠囊
    • 藥片

第14章 各地區的減充血劑市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 依類別分類的減充血劑市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國減充血劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Johnson & Johnson
    • Reckitt Benckiser Group plc
    • The Procter & Gamble Company
    • Haleon plc
    • Pfizer Inc.
    • Bayer AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
    • Perrigo Company plc
    • Viatris Inc.
Product Code: MRR-4A6A214484D8

The Decongestant Market is projected to grow by USD 11.59 billion at a CAGR of 6.45% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.03 billion
Estimated Year [2025] USD 7.48 billion
Forecast Year [2032] USD 11.59 billion
CAGR (%) 6.45%

A concise orientation to the evolving decongestant ecosystem highlighting clinical, regulatory, and commercial signals that demand executive attention

The decongestant landscape is undergoing rapid change driven by shifts in consumer behavior, regulatory emphasis on safety, and evolving channels of care delivery. This executive summary introduces key thematic drivers shaping product development and commercialization, and it frames the subsequent sections that examine structural shifts, tariff implications, segmentation intelligence, regional dynamics, and competitive behavior. The goal here is to orient senior decision-makers to the major forces that will affect product lifecycles, supply chains, and distribution strategies over the near term.

To provide immediate relevance for strategy discussions, the analysis synthesizes clinical, regulatory, and commercial signals that matter to manufacturers, distributors, and healthcare providers. It emphasizes where margin pressure may emerge, the role of differentiation through formulation and delivery technology, and the strategic responses that successful organizations are employing. By focusing on actionable insights, this introduction sets expectations for how the remainder of the document deepens understanding and supports priority-setting for executives and functional leaders.

How product innovation, regulatory tightening, and channel digitization are reshaping competitive and commercial strategies across the decongestant sector

The decongestant market is experiencing transformative shifts as technological innovation, patient expectations, and health system priorities converge. First, delivery format innovation is altering competitive dynamics; advances in metered-dose nasal sprays and single-dose drop technologies are enabling differentiated safety profiles and improved dosing accuracy. At the same time, digital health integration is accelerating adoption of e-prescribing and online pharmacy channels, which in turn influences packaging, patient education, and post-market surveillance requirements.

In parallel, regulatory scrutiny and pharmacovigilance practices are tightening around systemic exposure and adverse event reporting, prompting manufacturers to invest in reformulation and bioavailability studies. Moreover, consumer preferences are trending toward convenience and transparency, with over-the-counter positioning and clear labeling becoming pivotal in retail decision-making. Consequently, companies must reconcile R&D investments, regulatory pathways, and omnichannel distribution plans to maximize product uptake and minimize compliance risk. These shifts collectively signal that incremental product changes are insufficient; instead, firms need coordinated strategies across scientific, commercial, and regulatory functions to capitalize on emerging opportunities.

The downstream effects of 2025 tariff changes on supply chain resilience, procurement strategy, and commercial pricing structures in decongestant manufacturing

United States tariff adjustments announced for 2025 introduce a set of cumulative effects that influence raw material sourcing, finished-goods pricing, and supplier selection. Tariff rebalancing has a magnifying effect on cost structures for manufacturers that rely on cross-border inputs for active pharmaceutical ingredients and packaging components. As a result, procurement teams are being forced to reevaluate supplier portfolios, accelerate qualification of alternative vendors, and renegotiate supply agreements to protect gross margins.

Beyond direct cost implications, tariffs create strategic incentives for reshoring and regionalization of manufacturing capacity, particularly for higher-value formulations and controlled delivery systems. This trend is accompanied by increased capital allocation toward supply continuity measures, such as dual-sourcing strategies and buffer inventory for critical components. In addition, price pressures at the wholesale level cascade to distribution partners and, in some cases, influence formulary positioning and reimbursement discussions. Taken together, the tariff environment is prompting a more holistic approach to cost-to-serve modeling, requiring coordination among procurement, regulatory, and commercial teams to manage both price and access outcomes.

A layered segmentation framework explaining how product form, administration route, distribution pathways, and end-user cohorts drive strategic prioritization

A granular view of market dynamics requires attention to multiple segmentation frameworks that define product performance and customer interactions. Based on Product Type, market is studied across Drops, Nasal Sprays, and Tablets & Capsules and the Drops category is further analyzed across Multi Dose and Single Dose while the Nasal Sprays category is further analyzed across Metered Dose and Standard Spray and the Tablets & Capsules category is further analyzed across Extended Release and Immediate Release, which informs formulation choices, packaging design, and user instructions. Based on Route Of Administration, market is studied across Nasal and Oral, highlighting distinct clinical considerations, onset of action expectations, and patient preference drivers that influence point-of-care recommendations.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies and the Hospital Pharmacies segment is further analyzed across Private and Public while the Online Pharmacies segment is further analyzed across Branded Websites and Third-Party Platforms and the Retail Pharmacies segment is further analyzed across Chain Pharmacies and Independent Pharmacies, clarifying where channel economics and regulatory controls differ. Based on End User, market is studied across Adults, Geriatric, and Pediatrics and the Pediatrics segment is further analyzed across Adolescents, Children, and Infants, which impacts labeling, dosing forms, and caregiver communication strategies. Based on Prescription Status, market is studied across Over The Counter and Prescription, underlining how regulatory pathways and marketing permissions shape available promotion levers. Based on Form, market is studied across Liquid, Semi Solid, and Solid and the Liquid category is further analyzed across Suspension and Syrup while the Semi Solid category is further analyzed across Gel and Ointment and the Solid category is further analyzed across Capsule and Tablet, informing manufacturing investments and shelf-life trade-offs. Interpreting these segmentation layers together helps teams prioritize portfolio development and channel investments based on clinical positioning, regulatory constraints, and patient-centric design considerations.

Comparative regional playbooks for the decongestant sector that reconcile global platform efficiencies with local regulatory, payer, and channel realities

Regional dynamics vary significantly and require tailored strategies to succeed across distinct regulatory, payer, and channel environments. The Americas region is characterized by high regulatory scrutiny in certain jurisdictions, established over-the-counter ecosystems, and a mature retail pharmacy footprint where brand loyalty and point-of-sale placement remain influential. Meanwhile, in Europe, Middle East & Africa the regulatory mosaic is more fragmented across countries, presenting both barriers and opportunities for differentiated registration strategies and cross-border distribution solutions; localized labeling and pharmacovigilance programs frequently determine the speed of market entry.

In the Asia-Pacific region, growth vectors are often driven by rapid urbanization, expanding e-commerce adoption, and diverse healthcare access models that require nimble channel strategies. Consequently, product formats that emphasize convenience and patient education tend to achieve faster uptake in urban centers, whereas stable, long-shelf-life formulations resonate in areas with limited cold-chain infrastructure. Given these contrasts, regional playbooks should balance global platform efficiencies with local adaptation, aligning manufacturing footprints, regulatory dossiers, and marketing messages to the specific attributes of each geography.

How industry frontrunners are aligning formulation, supply chain resilience, and omnichannel engagement to secure sustainable competitive advantage

Leading companies in the decongestant space are converging on a set of strategic behaviors that emphasize integrated product development, distribution flexibility, and evidence generation. Several organizations are investing in formulation upgrades and delivery technologies to differentiate on safety and onset of action, while others are prioritizing label expansions and lifecycle management to extend product relevance. At the same time, partnerships between manufacturers and digital pharmacy platforms are becoming more common as firms seek to optimize patient access, adherence support, and real-world evidence collection.

Competitive positioning increasingly reflects sophistication in supply chain planning and regulatory strategy. Firms that proactively manage ingredient sourcing, regulatory filings, and pharmacovigilance demonstrate greater resilience to both policy shifts and demand fluctuations. In addition, companies that cultivate direct-to-consumer education programs and omnichannel sales capabilities are better positioned to capture shifts from traditional retail to online procurement. Overall, the competitive landscape rewards organizations that integrate scientific rigor with commercial agility and an explicit focus on end-user needs.

High-impact strategic moves for manufacturers to secure resilience and accelerate adoption through supply diversification, innovation, and omnichannel execution

Industry leaders should adopt a set of prioritized actions that protect margin, accelerate product uptake, and mitigate regulatory risk. First, strengthen supplier diversification and qualification processes to reduce exposure to tariff shocks and single-source disruptions, while concurrently investing in scenario-based cost-to-serve models that inform pricing and contractual levers. Second, accelerate reformulation and delivery innovation investments where clinical differentiation can be demonstrated and marketed credibly, with the goal of improving safety profiles and convenience for key end-user cohorts.

Third, expand omnichannel capabilities by integrating online pharmacy partnerships with brick-and-mortar distribution plans and tailored patient support programs; this will improve access while generating richer adherence and outcomes data. Fourth, enhance regulatory and pharmacovigilance functions to shorten approval timelines for label changes and to proactively manage safety communications. Finally, align commercial incentives across sales, medical affairs, and supply chain teams to ensure coordinated execution, faster response to market signals, and better stewardship of promotional resources.

A transparent mixed-methods approach combining expert interviews, regulatory analysis, and scenario testing to underpin actionable conclusions

This research synthesizes primary qualitative insights with secondary data streams to produce evidence-based, action-oriented conclusions. Primary research comprises structured interviews with industry stakeholders including formulation scientists, regulatory affairs leaders, procurement executives, and pharmacy directors, combined with targeted expert panels to validate interpretive findings. Secondary inputs include regulatory guidance documents, clinical literature relating to decongestant pharmacology and safety, patent landscape reviews, and public filings that illuminate corporate strategy and supply chain arrangements.

Analytical methods integrate thematic coding of qualitative interviews, cross-validation of regulatory trends against published guidance, and scenario analysis to test the resilience of supply chain and pricing strategies under tariff and policy permutations. Throughout the process, methodological rigor was maintained through source triangulation and transparent documentation of assumptions so that users can trace how specific conclusions were derived and apply the approach to internal decision models.

Consolidated implications and strategic priorities that executives must act on to secure long-term resilience and commercial relevance in the decongestant space

The cumulative analysis reveals that success in the decongestant market will hinge on integrated strategies that bridge science, supply chain, and commercial execution. In short, organizations that invest in delivery system innovation, build resilient and diversified supply networks, and align omnichannel distribution with compelling patient education will be best positioned to navigate regulatory tightening and tariff-driven cost pressures. By contrast, firms that treat these challenges in isolation risk erosion of margin and slower adoption of new or reformulated products.

Looking ahead, coordination across functions-R&D, regulatory, procurement, and commercial-will be a defining competency. Stakeholders should prioritize initiatives that deliver measurable improvements in safety, convenience, and access, while maintaining flexibility to adapt to sudden policy changes. Ultimately, the synthesis underscores a pragmatic pathway: actionable, cross-functional programs grounded in evidence will yield sustainable advantage more reliably than incremental, siloed responses.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising consumer preference for sugar-free, alcohol-free decongestant syrups with natural extracts boosting clean label appeal
  • 5.2. Integration of novel nanoemulsion technology to improve mucosal absorption in topical decongestant formulations
  • 5.3. Expansion of direct-to-consumer subscription models for seasonal decongestant therapies with personalized dosage reminders
  • 5.4. Growth of e-commerce channels for plant-derived essential oil inhalers targeting holistic respiratory relief audience
  • 5.5. Increasing regulatory scrutiny on pseudoephedrine sales driving innovation in non-stimulant decongestant alternatives
  • 5.6. Rising interest in dual-action decongestant-antihistamine combination products for year-round allergy and sinus relief
  • 5.7. Emergence of smartphone-connected nasal spray devices enabling usage tracking and AI-driven dosage optimization

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Decongestant Market, by Product Type

  • 8.1. Drops
    • 8.1.1. Multi Dose
    • 8.1.2. Single Dose
  • 8.2. Nasal Sprays
    • 8.2.1. Metered Dose
    • 8.2.2. Standard Spray
  • 8.3. Tablets & Capsules
    • 8.3.1. Extended Release
    • 8.3.2. Immediate Release

9. Decongestant Market, by Route Of Administration

  • 9.1. Nasal
  • 9.2. Oral

10. Decongestant Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
    • 10.1.1. Private
    • 10.1.2. Public
  • 10.2. Online Pharmacies
    • 10.2.1. Branded Websites
    • 10.2.2. Third-Party Platforms
  • 10.3. Retail Pharmacies
    • 10.3.1. Chain Pharmacies
    • 10.3.2. Independent Pharmacies

11. Decongestant Market, by End User

  • 11.1. Adults
  • 11.2. Geriatric
  • 11.3. Pediatrics
    • 11.3.1. Adolescents
    • 11.3.2. Children
    • 11.3.3. Infants

12. Decongestant Market, by Prescription Status

  • 12.1. Over The Counter
  • 12.2. Prescription

13. Decongestant Market, by Form

  • 13.1. Liquid
    • 13.1.1. Suspension
    • 13.1.2. Syrup
  • 13.2. Semi Solid
    • 13.2.1. Gel
    • 13.2.2. Ointment
  • 13.3. Solid
    • 13.3.1. Capsule
    • 13.3.2. Tablet

14. Decongestant Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Decongestant Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Decongestant Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Johnson & Johnson
    • 17.3.2. Reckitt Benckiser Group plc
    • 17.3.3. The Procter & Gamble Company
    • 17.3.4. Haleon plc
    • 17.3.5. Pfizer Inc.
    • 17.3.6. Bayer AG
    • 17.3.7. Sanofi S.A.
    • 17.3.8. Teva Pharmaceutical Industries Ltd.
    • 17.3.9. Perrigo Company plc
    • 17.3.10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DECONGESTANT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DECONGESTANT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS DECONGESTANT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DECONGESTANT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL DECONGESTANT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL DECONGESTANT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. DECONGESTANT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. DECONGESTANT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DECONGESTANT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DECONGESTANT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL DECONGESTANT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL DECONGESTANT MARKET SIZE, BY DROPS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL DECONGESTANT MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL DECONGESTANT MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL DECONGESTANT MARKET SIZE, BY METERED DOSE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL DECONGESTANT MARKET SIZE, BY STANDARD SPRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL DECONGESTANT MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL DECONGESTANT MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL DECONGESTANT MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL DECONGESTANT MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL DECONGESTANT MARKET SIZE, BY PRIVATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL DECONGESTANT MARKET SIZE, BY PUBLIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL DECONGESTANT MARKET SIZE, BY BRANDED WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL DECONGESTANT MARKET SIZE, BY THIRD-PARTY PLATFORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL DECONGESTANT MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL DECONGESTANT MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL DECONGESTANT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL DECONGESTANT MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL DECONGESTANT MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL DECONGESTANT MARKET SIZE, BY PEDIATRICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL DECONGESTANT MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL DECONGESTANT MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL DECONGESTANT MARKET SIZE, BY INFANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL DECONGESTANT MARKET SIZE, BY OVER THE COUNTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL DECONGESTANT MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL DECONGESTANT MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL DECONGESTANT MARKET SIZE, BY LIQUID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL DECONGESTANT MARKET SIZE, BY SUSPENSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL DECONGESTANT MARKET SIZE, BY SYRUP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL DECONGESTANT MARKET SIZE, BY SEMI SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL DECONGESTANT MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL DECONGESTANT MARKET SIZE, BY OINTMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL DECONGESTANT MARKET SIZE, BY SOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL DECONGESTANT MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL DECONGESTANT MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL DECONGESTANT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL DECONGESTANT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. AMERICAS DECONGESTANT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 262. AMERICAS DECONGESTANT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 263. AMERICAS DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. AMERICAS DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. AMERICAS DECONGESTANT MARKET SIZE, BY DROPS, 2018-2024 (USD MILLION)
  • TABLE 266. AMERICAS DECONGESTANT MARKET SIZE, BY DROPS, 2025-2032 (USD MILLION)
  • TABLE 267. AMERICAS DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 268. AMERICAS DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 269. AMERICAS DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 270. AMERICAS DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 271. AMERICAS DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. AMERICAS DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. AMERICAS DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. AMERICAS DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. AMERICAS DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 276. AMERICAS DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS DECONGESTANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS DECONGESTANT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS DECONGESTANT MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS DECONGESTANT MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS DECONGESTANT MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS DECONGESTANT MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 294. AMERICAS DECONGESTANT MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. NORTH AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2024 (USD MILLION)
  • TABLE 300. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2025-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 302. NORTH AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 304. NORTH AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 308. NORTH AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 309. NORTH AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 310. NORTH AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 311. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 312. NORTH AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 313. NORTH AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 314. NORTH AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 315. NORTH AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NORTH AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
  • TABLE 318. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2025-2032 (USD MILLION)
  • TABLE 319. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 320. NORTH AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 321. NORTH AMERICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2024 (USD MILLION)
  • TABLE 322. NORTH AMERICA DECONGESTANT MARKET SIZE, BY FORM, 2025-2032 (USD MILLION)
  • TABLE 323. NORTH AMERICA DECONGESTANT MARKET SIZE, BY LIQUID, 2018-2024 (USD MILLION)
  • TABLE 324. NORTH AMERICA DECONGESTANT MARKET SIZE, BY LIQUID, 2025-2032 (USD MILLION)
  • TABLE 325. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2018-2024 (USD MILLION)
  • TABLE 326. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SEMI SOLID, 2025-2032 (USD MILLION)
  • TABLE 327. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SOLID, 2018-2024 (USD MILLION)
  • TABLE 328. NORTH AMERICA DECONGESTANT MARKET SIZE, BY SOLID, 2025-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. LATIN AMERICA DECONGESTANT MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2018-2024 (USD MILLION)
  • TABLE 334. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DROPS, 2025-2032 (USD MILLION)
  • TABLE 335. LATIN AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2018-2024 (USD MILLION)
  • TABLE 336. LATIN AMERICA DECONGESTANT MARKET SIZE, BY NASAL SPRAYS, 2025-2032 (USD MILLION)
  • TABLE 337. LATIN AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2018-2024 (USD MILLION)
  • TABLE 338. LATIN AMERICA DECONGESTANT MARKET SIZE, BY TABLETS & CAPSULES, 2025-2032 (USD MILLION)
  • TABLE 339. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 340. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 341. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 342. LATIN AMERICA DECONGESTANT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 343. LATIN AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 344. LATIN AMERICA DECONGESTANT MARKET SIZE, BY HOSPITAL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 345. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 346. LATIN AMERICA DECONGESTANT MARKET SIZE, BY ONLINE PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 347. LATIN AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2018-2024 (USD MILLION)
  • TABLE 348. LATIN AMERICA DECONGESTANT MARKET SIZE, BY RETAIL PHARMACIES, 2025-2032 (USD MILLION)
  • TABLE 349. LATIN AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 350. LATIN AMERICA DECONGESTANT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 351. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2018-2024 (USD MILLION)
  • TABLE 352. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PEDIATRICS, 2025-2032 (USD MILLION)
  • TABLE 353. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2018-2024 (USD MILLION)
  • TABLE 354. LATIN AMERICA DECONGESTANT MARKET SIZE, BY PRESCRIPTION STATUS, 2025-2032 (USD MILLION)
  • TABLE 355. LATIN AMERICA DECONGESTANT MARKET SIZE, BY FORM, 2018-2024 (US